Targeting Alzheimer's Disease

Targeted delivery approaches for cancer therapeutics have presented a steep rise over the past few decades. Based on years of extensive experience in delivery system design and development, Creative Biolabs offers a full range of high-quality targeted delivery services for customers around the world. With the help of our professional scientists, we are confident in providing custom targeted delivery services for Alzheimer's disease (AD) to meet every customer's requirements.

Alzheimer's Disease

AD is a type of progressive neurodegenerative disorder disease characterized by memory, cognition and behavioral impairment (dementia), and it eventually causes mood fluctuation and fatal delirium. The increasing proportion of aging individuals has made AD the most predominant neurodegenerative disorder. AD is a worldwide concern, which was predicted to by 2030 with around 65.7 million clinical cases. So far, scientists have developed some drug candidates such as tacrine, donepezil, rivastigmine, galantamine (AChE inhibitors), and memantine (NMDA inhibitor). Although these drug candidates were significant in preclinical studies, they failed to perform the anticipated efficacy in human trials due to poor pharmacokinetics or low bioavailability, chemical nature, volatility of evaluated drug candidates in biological system. Currently, nanotechnology is widely used in drug delivery systems,which can improve the bioavailability and kinetic profile of drugs in biological systems.

Fig.1 Graphical representation of a few successful nano-carriers adapted in AD nano-therapeutics. (Karthivashan, 2018)

Delivery System Targeting Alzheimer's Disease

Advances in nanotechnology facilitate targeting drugs to specific molecular targets and safely delivering drugs to specific sites of action. The slow release of nano-drug delivery systems improves the controlled release profile of loaded drugs, thereby minimizing the dosage-regimen. Thus, the overall effectiveness of drug candidates can be promoted by adapting nano-drug delivery systems in AD therapeutics. A subsequent strategy involves binding the drug molecules with moieties such as small proteins, peptides, antibodies and trigger receptor-mediated endocytosis.

Fig.2 Schematic representation of potential pathways involved in nanoparticle-mediated drug trafficking across blood brain barrier associated with AD-nanotherapeutics. (Karthivashan, 2018)

Cell penetrating peptides (CPPs) such as SynB peptides are widely used to transport small molecule drugs across the blood brain barrier (BBB). The researcher successfully demonstrated the drug-shuttling potential of CPP modified liposomes across the brain endothelial barriers both in vitro and in vivo. In addition, anti-transferrin tagged multifunctional liposomes have been successfully formulated and confirmed its potential drug delivery of loaded curcumin derivatives across BBB via transferrin receptor-mediated endocytosis. Cationic liposomes are also used to improve the permeability of loaded polyanionic DNA, RNA entities, due to its electrostatic interface with the negatively charged cell membranes and its ability to cross BBB via adsorption-mediated transcytosis or endocytosis.

What Can We Do for You?

Advances in targeted delivery lead to a rise in potential therapeutic strategies against AD progression. The appropriate design and fabrication of NPs effectively surpass conventional neurotherapeutic hurdle and enhances the physicochemical properties of drug candidates in biological systems. With our comprehensive module delivery systems, Creative Biolabs is dedicated to the development of innovative targeted carrier that has a higher specificity and higher sensitivity, to help increase the accuracy of the clinical diagnosis and treatment. Please contact us for more information if you are interested in our services.

Reference

1. Karthivashan, G.; et al. Therapeutic strategies and nano-drug delivery applications in management of ageing alzheimer's disease. Drug Delivery. 2018, 25(1), 307-320.

Our services are For Research Use Only. We do not provide services to individuals.